BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years
Eun Jung Jang, Young June Choe, Ryu Kyung Kim, Young-Joon Park
IF 18JAMA Pediatrics
초록
This cohort study examines data for all children aged 5 to 11 years in South Korea to gauge the effectiveness of the BNT162b2 vaccine when the Omicron variant was the dominant SARS-CoV-2 infection in the country.